2024-03-24 10:37:50
Quibim, a pioneering global bioengineering company for precision medicine, today announces the launch of a new product, QP-Liver, which improves the diagnosis of diffuse liver disease through highly accurate quantification of tissue fat and iron from MRI scans. It has been CE and UKCA marked for the EU and UK respectively, meaning it is approved for use in these markets.
Chronic liver disease is a significant burden, causing high morbidity and mortality rates and medical effort. According to the World Health Organization (WHO), liver diseases account for approximately 2 million global deaths each year. Leveraging Quibim’s AI models, QP-Liver provides highly accurate automated liver segmentation and correlates fat and iron quantification with reference digital pathology data, enabling researchers and clinicians to leverage personalized liver disease management. This includes early detection, accurate monitoring and tailored treatment plans. The tool also reduces the need for invasive biopsies, and provides solid insights for informed decision-making and increased patient care.
The platform includes a post-processing solution for fat and iron quantification that performs fully automated analyzes of abdominal MRIs containing Multi-Echo Chemical Shift (MECSE) sequences that can accurately detect and quantify fat content. It can then create parametric maps of fat and iron, offering detailed analysis by processing each tiny 3D element of the scan individually to create what’s known as voxel resolution. This is used to create a structured quantitative report that compares liver values with normative data.
By quantifying iron and fat simultaneously, Quivib’s tool offers comprehensive information for assessing steatosis and iron overload, correcting for confounding factors and biases inherent in conventional, non-concurrent methods. This enables more accurate measurements to assess the severity of the disease and improves the quality of radiologists’ reports and decisions – performing processes within the health institutions. Researchers can also use QP-Liver to correlate quantification with digital pathology data, enabling comprehensive analysis.
Coexistence of fat and iron in the liver is a risk factor for hepatocarcinoma and these findings should be treated early. QP-Liver represents a significant leap forward in liver imaging analysis. By automating liver segmentation and simultaneous quantification of tissue fat and iron instead of independently, it enables the highest accuracy and allows physicians to make more informed diagnoses for patients with diffuse liver disease. We believe the tool’s impact on liver disease diagnosis is truly remarkable, and it demonstrates the intersection of cutting-edge AI, quantitative algorithms, and healthcare.
It is important to emphasize that the mission to accelerate real-life early detection of cancer and other diseases such as liver disease is truly an international group effort at every stage. We are acutely aware of the vital role our research, healthcare and pharmaceutical partners play in ensuring that the technology adapts to patient care, which is why receiving regulatory backing for QP-Liver is a milestone. We look forward to seeing the tool in use across the EU and the UK in the near future.”
Angel Albrich-Bayari, co-founder and CEO of Quivim
#Quibim #introduces #QPLiver #improve #diagnosis #liver #diseases #MRI #analysis